Provenge Tops 500 Scripts Since Approval; Most Local Medicare Contractors Will Cover Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Dendreon gave an update on the launch of the prostate cancer vaccine during its earnings call on Aug. 3.
You may also be interested in...
Dendreon Extends Provenge Supply In Agreement With GSK
Supply arrangement won't impact availability of Provenge this year; first shipment from GSK will begin in 2011, according to a regulatory filing.
Dendreon Extends Provenge Supply In Agreement With GSK
Supply arrangement won't impact availability of Provenge this year; first shipment from GSK will begin in 2011, according to a regulatory filing.
CMS Decision To Conduct Provenge NCA Could Be "Chilling To Future Innovation," BIO's Greenwood Says
BIO CEO Jim Greenwood discusses his views on the Medicare national coverage analysis for Dendreon's prostate cancer immunotherapy Provenge with "The Pink Sheet" DAILY.